Spots Global Cancer Trial Database for combination chemotherapy
Every month we try and update this database with for combination chemotherapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer | NCT00001499 | Carcinoma, Non-... Lung Neoplasms | paclitaxel cisplatin chest radiother... | - | National Institutes of Health Clinical Center (CC) | |
| Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC | NCT03201146 | Lung Cancer Non Small Cell ... Combination Che... Apatinib | Apatinib AP or AC Apatinib 250mg Apatinib 500mg Apatinib 750mg | 18 Years - 70 Years | West China Hospital | |
| The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer | NCT00345059 | Advanced Non-Sm... | docetaxel vinorelbine gemcitabine capecitabine | - 75 Years | National Cancer Institute, Naples | |
| A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis | NCT01782339 | Germ Cell Tumou... | Combination Che... | 16 Years - 65 Years | Barts & The London NHS Trust | |
| Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma | NCT01204372 | Metastatic Panc... | Gemcitabine - T... | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer) | NCT03053297 | Carcinoma, Non-... | Patient Reporte... | 18 Years - | AstraZeneca | |
| Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer | NCT00587145 | Stomach Neoplas... | S-1,Docetaxel | 18 Years - 70 Years | National Cancer Center, Korea | |
| PAXG Out in the Country | NCT04480268 | Pancreatic Duct... | PAXG regimen (c... | 18 Years - 75 Years | IRCCS San Raffaele | |
| Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations | NCT01206049 | Cholangiocarcin... | Gemcitabine Oxaliplatin Capecitabine Panitumumab Bevacizumab | 18 Years - | Vejle Hospital | |
| Phase II 5-Azacytidine Plus VPA Plus ATRA | NCT00326170 | Myelodysplastic... Acute Myelogeno... | 5-Azacytidine (... Valproic Acid All-Trans Retin... | 3 Years - | M.D. Anderson Cancer Center | |
| CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients | NCT00526643 | Non-Small Cell ... | gemcitabine cisplatin | 18 Years - 70 Years | National Cancer Institute, Naples | |
| Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) | NCT03111732 | Biliary Tract N... Cholangiocarcin... Bile Duct Cance... Liver Cancer Gallbladder Can... | Pembrolizumab (... Oxaliplatin Capecitabine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma | NCT01204372 | Metastatic Panc... | Gemcitabine - T... | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer | NCT04152057 | Breast Cancer HER2 Positive Combination Che... | Pyrotinib Malea... Albumin Paclita... Trastuzumab | 18 Years - 70 Years | West China Hospital | |
| Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations | NCT01206049 | Cholangiocarcin... | Gemcitabine Oxaliplatin Capecitabine Panitumumab Bevacizumab | 18 Years - | Vejle Hospital | |
| Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia | NCT05827549 | Acute Lymphoid ... | Blincyto | 1 Year - 22 Years | Asan Medical Center | |
| Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer | NCT01020864 | Head and Neck N... | Cetuximab Carboplatin Vinorelbine | 18 Years - 80 Years | Odense University Hospital | |
| S-1 vs Capecitabine in the Elderly and/or Poor Performance Status Patients With Recurrent or Metastatic Gastric Cancer | NCT00580359 | Stomach Neoplas... | S-1, capecitabi... | 60 Years - 85 Years | National Cancer Center, Korea | |
| S-1 vs Capecitabine in the Elderly and/or Poor Performance Status Patients With Recurrent or Metastatic Gastric Cancer | NCT00580359 | Stomach Neoplas... | S-1, capecitabi... | 60 Years - 85 Years | National Cancer Center, Korea | |
| A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer | NCT00512681 | Stomach Neoplas... | Irinotecan, Oxa... | 18 Years - | National Cancer Center, Korea | |
| CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients | NCT00526643 | Non-Small Cell ... | gemcitabine cisplatin | 18 Years - 70 Years | National Cancer Institute, Naples | |
| Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer | NCT00506844 | Rectal Neoplasm... Neoadjuvant Tre... | Cetuximab, Irin... | 18 Years - 75 Years | National Cancer Center, Korea | |
| Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer | NCT00506571 | Colorecal Neopl... Secondary | S-1, irinotecan... | 18 Years - | National Cancer Center, Korea | |
| Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer | NCT00506844 | Rectal Neoplasm... Neoadjuvant Tre... | Cetuximab, Irin... | 18 Years - 75 Years | National Cancer Center, Korea | |
| Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma | NCT01204372 | Metastatic Panc... | Gemcitabine - T... | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer | NCT00512681 | Stomach Neoplas... | Irinotecan, Oxa... | 18 Years - | National Cancer Center, Korea | |
| A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer | NCT00512681 | Stomach Neoplas... | Irinotecan, Oxa... | 18 Years - | National Cancer Center, Korea | |
| Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer | NCT00506571 | Colorecal Neopl... Secondary | S-1, irinotecan... | 18 Years - | National Cancer Center, Korea | |
| A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung | NCT02185690 | Lungcancer | Binimetinib Pemetrexed Carboplatin | 18 Years - 90 Years | University Health Network, Toronto | |
| A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer | NCT00512681 | Stomach Neoplas... | Irinotecan, Oxa... | 18 Years - | National Cancer Center, Korea | |
| A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy | NCT00506207 | Colorectal Neop... Gastric Neoplas... Secondary | S-1, Irinotecan... | 18 Years - | National Cancer Center, Korea | |
| Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma | NCT00992134 | Lymphoma, Mantl... | Rituximab, Bend... | 18 Years - | St. Bortolo Hospital | |
| A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia | NCT06148506 | HR+HER2- Advanc... | Ribociclib Combination che... | 18 Years - 99 Years | Novartis | |
| Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia | NCT05827549 | Acute Lymphoid ... | Blincyto | 1 Year - 22 Years | Asan Medical Center | |
| A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis | NCT01782339 | Germ Cell Tumou... | Combination Che... | 16 Years - 65 Years | Barts & The London NHS Trust | |
| A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia | NCT06148506 | HR+HER2- Advanc... | Ribociclib Combination che... | 18 Years - 99 Years | Novartis | |
| The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer | NCT00345059 | Advanced Non-Sm... | docetaxel vinorelbine gemcitabine capecitabine | - 75 Years | National Cancer Institute, Naples | |
| A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung | NCT02185690 | Lungcancer | Binimetinib Pemetrexed Carboplatin | 18 Years - 90 Years | University Health Network, Toronto | |
| Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer | NCT04152057 | Breast Cancer HER2 Positive Combination Che... | Pyrotinib Malea... Albumin Paclita... Trastuzumab | 18 Years - 70 Years | West China Hospital | |
| Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer | NCT00001499 | Carcinoma, Non-... Lung Neoplasms | paclitaxel cisplatin chest radiother... | - | National Institutes of Health Clinical Center (CC) | |
| A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer | NCT00504192 | Advanced Biliar... Gemcitabine Oxaliplatin Combination Che... Efficacy | Gemcitabine and... | 18 Years - | Soonchunhyang University Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
